Financial Performance - The company's operating revenue for Q3 2025 reached ¥93,779,111.15, an increase of 29.80% compared to the same period last year[3] - The total profit for the period was ¥20,072,789.92, reflecting a significant increase of 118.52% year-over-year[3] - The net profit attributable to shareholders was ¥11,878,406.38, marking a substantial growth of 283.59% compared to the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥7,791,833.40, which is an increase of 2,174.87% year-over-year[3] - Total profit for the year-to-date increased by 75.66%, driven by higher revenue leading to improved gross profit[9] - Net profit attributable to shareholders for the year-to-date was up by 81.48%, primarily due to revenue growth[9] - The total profit for the first three quarters of 2025 is CNY 68,924,070.17, compared to CNY 39,238,029.92 in the same period of 2024, representing an increase of approximately 75.8%[33] - The net profit for the first three quarters of 2025 is CNY 49,056,755.23, up from CNY 26,635,103.70 in 2024, indicating an increase of about 84.0%[33] Revenue and Growth - For the first three quarters of 2025, the company achieved operating revenue of CNY 271.53 million, a year-on-year increase of 25.79%[20] - The main business revenue reached CNY 271.18 million, reflecting a growth of 25.83% compared to the same period last year[20] - The cell culture products business generated revenue of CNY 238.60 million, marking a significant increase of 32.56% year-on-year, solidifying its position as the core revenue driver[20] - The CDMO service business reported revenue of CNY 32.58 million, showing a slight decline of 8.25% year-on-year due to external environment and customer demand fluctuations[21] Expenses and Costs - Research and development expenses totaled ¥12,235,563.44, accounting for 13.05% of operating revenue, an increase of 1.13 percentage points[4] - Research and development expenses rose to ¥36,377,735.69 in the first three quarters of 2025, up from ¥23,993,014.16 in 2024, marking an increase of 51.6%[32] - Total operating costs for the first three quarters of 2025 were ¥216,359,655.21, up from ¥186,064,262.52 in 2024, reflecting a growth of 16.2%[32] Cash Flow - The cash flow from operating activities for the period was ¥38,943,843.04, a decrease of 7.88% compared to the same period last year[3] - Cash flow from operating activities increased by 70.62% year-to-date, resulting from improved sales revenue and collection of receivables[9] - The operating cash flow for the first three quarters of 2025 is CNY 100,287,763.01, compared to CNY 58,777,458.30 in 2024, reflecting a growth of approximately 70.6%[36] - The company reported a decrease in cash flow from financing activities, with a net cash flow of -CNY 51,709,069.75 in 2025 compared to -CNY 95,877,104.85 in 2024, indicating an improvement[37] Assets and Liabilities - The total assets at the end of the period were ¥2,272,126,966.73, a slight decrease of 0.62% from the end of the previous year[4] - The company's cash and cash equivalents decreased to ¥741,681,201.59 as of September 30, 2025, from ¥891,143,542.80 at the end of 2024, a decline of 16.8%[28] - Total liabilities decreased to ¥172,553,849.21 as of September 30, 2025, from ¥190,970,352.87 at the end of 2024, a reduction of 9.6%[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 3,682[12] - The top shareholder, Xiao Zhihua, holds 24.92% of the shares, totaling 28,301,943 shares[12] Strategic Initiatives - The company is focusing on expanding its market presence and investing in new product development to drive future growth[32] - The company successfully passed the EU Qualified Person audit, confirming compliance with EU GMP requirements, which supports its expansion into international markets[25] - The company is in the process of a major asset restructuring, with responses to regulatory inquiries completed and awaiting further approvals[27] Stock and Incentives - The company’s stock incentive plan saw the registration of 271,400 shares, increasing the total share capital from 113,548,754 shares to 113,820,154 shares[16] - The company’s antibody series culture medium was selected as one of the 200 innovative product application demonstration cases in the Yangtze River Delta region, highlighting its technological innovation[24] Accounting Standards - The company has not adopted new accounting standards for the year 2025[38]

Core Insights - The company reported a third-quarter revenue of 93.78 million yuan, representing a year-on-year increase of 29.80% [1] - The net profit for the third quarter was 11.88 million yuan, showing a significant year-on-year growth of 283.59% [1] - For the first three quarters, the total revenue reached 272 million yuan, which is a 25.79% increase compared to the same period last year [1] - The net profit for the first three quarters amounted to 49.43 million yuan, reflecting an impressive year-on-year growth of 81.48% [1]

Core Viewpoint - The establishment of Shanghai's first biomanufacturing industry fund aims to integrate resources from enterprises, universities, and research institutions to promote technological breakthroughs and business growth [1] Group 1 - The fund is initiated by Guotou Xian Dao Fund under Shanghai Guotou Company, in collaboration with Daotong Investment and Aopumai [1] - The fund adopts a "C (industry chain leading enterprises) + VC (professional investment institutions)" dual-driven model [1] - Aopumai is recognized as a leading enterprise in cell culture media, leveraging its industry advantages [1] Group 2 - Daotong Investment brings its expertise in early-stage medical and synthetic biology investments to the fund [1] - The fund aims to foster collaboration among key stakeholders in the biomanufacturing sector [1] - The initiative is expected to drive significant advancements in critical technologies within the industry [1]

Core Viewpoint - The first biomanufacturing industry fund in Shanghai has been officially established, aiming to integrate resources from enterprises, universities, and research institutions to promote key technological breakthroughs and corporate growth [1] Group 1: Fund Structure and Collaboration - The fund is empowered by the State Investment Company under Shanghai Guotou and co-initiated by Daotong Investment and Aopumai [1] - It adopts a "C (main industry chain enterprises) + VC (professional investment institutions)" dual-driven model [1] Group 2: Strategic Focus - Aopumai is positioned as a leading enterprise in cell culture media, leveraging its industry advantages [1] - Daotong brings expertise in early-stage medical and synthetic biology investments, enhancing the fund's strategic focus [1]

Group 1 - The "Shengyan Wanwu" Biomanufacturing Industry Value Partner Conference was held in Shanghai, where the first biomanufacturing industry fund in Shanghai was launched [1] - The fund is initiated by Daotong Investment and Aopumai, utilizing a "C (main industry chain enterprise) + VC (professional investment institution)" dual-driven model [1] - Aopumai, a leading company in cell culture media, and Daotong Investment, with experience in early-stage medical and synthetic biology investments, aim to integrate resources from enterprises, universities, and research institutions to promote technological breakthroughs and industry ecosystem development [1] Group 2 - Aopumai's Chairman, Xiao Zhihua, stated that the collaboration aims to merge Aopumai's industry experience with Daotong's investment expertise to discover and support "tomorrow's stars" in the biomanufacturing industry chain [3] - Aopumai, established in 2013 and listed on the Sci-Tech Innovation Board in 2022, specializes in providing cell culture solutions and end-to-end CDMO services, with over 18,000 square meters of GMP-compliant production facilities [3] - Daotong Investment, founded in 2015, focuses on early-stage investments and industry mergers in the life sciences sector, covering various investment opportunities in medical equipment, biotechnology, and other related fields [3]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights significant advancements in innovative drugs, particularly in the context of recent clinical trial results presented at the 2025 ESMO conference, showcasing the potential for new treatment options in various cancer types [12][19] - The report emphasizes the emergence of domestic drugs that have achieved notable efficacy in treating conditions such as NSCLC and HER2-positive breast cancer, indicating a shift in the competitive landscape [13][17] Summary by Sections 1. New Drug Developments - **2L EGFR Mutant NSCLC**: The drug Lukanosumab (sac-TMT) is the first to demonstrate both overall survival (OS) and progression-free survival (PFS) benefits in patients with TKI-resistant NSCLC, with mPFS of 8.3 months compared to 4.3 months for chemotherapy [13][14] - **HER2 Positive Breast Cancer**: The drug Ruikang Trastuzumab shows longer mPFS of 30.6 months compared to 8.3 months for the chemotherapy combination, indicating a promising new option for patients [17][18] - **T-Bren for Breast Cancer**: Early data from the T-Bren trial shows a clinical overall response rate (cORR) of 82.2% in HER2-positive patients, with mPFS of 18.0 months [19][20] - **2L HER2 Positive Gastric Cancer**: Anniotuzumab combined with chemotherapy shows significant improvements in mPFS (7.1 months vs 2.7 months) and mOS (19.6 months vs 11.5 months), suggesting a potential shift in treatment paradigms [21][24] 2. Market Performance - The pharmaceutical and biotechnology sector saw a 0.58% increase in October, underperforming the CSI 300 index by 2.67 percentage points, ranking 25th among 31 sub-industries [25][30] - The medical research outsourcing sector experienced the highest growth, up 5.47%, while other bioproduct sectors faced declines [30][34]

Core Insights - The "Biomanufacturing Industry Value Partners Conference" was successfully held in Shanghai, co-hosted by Aopumai Biotechnology Co., Ltd. and Daotong Investment, focusing on the latest trends and industrialization paths in biomanufacturing [1][2] - The first biomanufacturing industry fund in Shanghai was officially launched during the conference, aimed at injecting dual momentum of "capital + ecology" into industry development [1] - The biomanufacturing fund, initiated by Aopumai and Daotong Investment, adopts a dual-driven model combining industry chain leaders and professional investment institutions, focusing on integrating resources from enterprises, universities, and research institutes to promote technological breakthroughs and business growth [1][2] Company and Industry Summary - Aopumai's chairman, Xiao Zhihua, emphasized the goal of the biomanufacturing fund and the investment conference is to merge Aopumai's industry experience with Daotong's investment expertise to discover and support "tomorrow's stars" with core technologies in the biomanufacturing industry [2] - The establishment of the "Biomanufacturing Industry Value Partners" aims to promote ecological collaboration within the industry, with initial members including East China University of Science and Technology, Jiangnan University, Daotong Investment, Aopumai, Meihua Biotechnology, Novo Holdings, and the Shanghai Synthetic Biology Innovation Center, covering four major fields: capital, universities, research institutes, and enterprises [2]

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

数据显示，工银瑞信基金旗下1只基金位居奥浦迈十大流通股东。工银前沿医疗股票A（001717）二季 度增持125.08万股，持有股数290.01万股，占流通股的比例为3.75%。根据测算，今日浮亏损失约843.93 万元。 工银前沿医疗股票A（001717）成立日期2016年2月3日，最新规模93.3亿。今年以来收益27.82%，同类 排名1780/4218；近一年收益20.02%，同类排名2322/3869；成立以来收益236.3%。 工银前沿医疗股票A（001717）基金经理为赵蓓。 截至发稿，赵蓓累计任职时间10年342天，现任基金资产总规模164.25亿元，任职期间最佳基金回报 233.5%， 任职期间最差基金回报-29.38%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 10月22日，奥浦迈跌5.04%，截至发稿，报54.82元/股，成交1.03亿元，换手率1.62%，总市值62.40亿 元。 资料显示，上海奥浦迈生物科技股份有限公司位于上海市浦东新区紫萍路 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-090 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 271,400股。 本次股票上市流通总数为271,400股。 本次股票上市流通日期为2025 年 10 月 22 日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，上海奥浦迈生物科技股份有限公司（以 下简称"公司"或"奥浦迈"）于 2025 年 10 月 17 日收到中国证券登记结算有限责任 公司上海分公司出具的《证券变更登记证明》，公司已完成 2023 年限制性股票激 励计划（以下简称"本激励计划"）首次授予部分第二个归属期、预留授予部分第一 个归属期第一次股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 上海奥浦迈生物科技股份有限公司 关于 2023 年限制性股票激励计划首次授予部分第二个 归属期、预留授予部分第一个归属期第一次归属结果暨 股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完 ...